Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ORMP

ORAMED PHARMACEUTICALS INC.

Pharmaceutical Preparations · SIC 2834CIK 1176309Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$2.0M
Net Income FY2025
$64.0M
EPS (Basic, as reported)
$1.53
Net Margin FY2025
3202.5%
ROE FY2025
32.1%
Total Equity
$200.0M
Shares Out
42M
Business description

ORAMED PHARMACEUTICALS INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2008–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 1 → 2 +8% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue12233331—2
Cost of revenue0000—————(2)
Gross profit—————————0
Research & development(8)(10)(12)(14)(10)(21)(28)(9)(6)(6)
General & administrative(2)(3)(4)(4)(4)(6)(14)(8)(6)(9)
Operating income(10)(11)(14)(15)(12)(24)(41)(16)(13)(15)
Interest expense———————(2)(1)—
Interest & investment income———————0——
Other income (expense), net——————323(2)89
Pre-tax income(10)(10)(13)(14)(12)—(38)5(16)75
Income tax expense(1)0—0——0—(3)(11)
Net income(11)(10)(13)(14)(12)(23)(37)6(19)64
EPS — basic——————$0.94$0.14($0.48)$1.53
EPS — diluted——————$0.94$0.14($0.48)$1.50
Shares outstanding — basic (M)——————39404141
Shares outstanding — diluted (M)——————39414142

Showing the latest 10 of 18 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.